BioSpace News Archive

Lobe Sciences Ltd. (“Lobe” or the “Company”) (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical research studies, in established rodent models of mild traumatic brain injury/concussion (“mTBI”) and post-traumatic stress disorder (“PTSD”), using psilocybin plus N-Acetylcysteine (“NAC”).

Novian Health Inc. has been granted Breakthrough Device designation from the U.S. Food and Drug Administration for its Novilase®Interstitial Laser System and its proposed indication for use: the focal destruction of malignant breast tumors in adult women who seek a breast conserving procedure.

Shionogi to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETROJA ® (cefiderocol) Against Gram-Negative Pathogens

ReCode Therapeutics today announced that Company leadership will participate in three upcoming virtual investor conferences in October: Chardan 5th Annual Genetic Medicines Conference Format: Presentation Date: Monday, October 4, 2021

NovaBay ® Pharmaceuticals, Inc . announces it has entered into a definitive agreement to acquire DERMAdoctor, LLC, a privately-held company that commercializes dermatologist-developed skincare products

Fortress Biotech, Inc. announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the Benzinga Healthcare Small Cap Conference, scheduled to take place from September 29-30, 2021.

MAIA Biotechnology, Inc. announced today that it has appointed Steven M. Chaouki to its Board of Directors. Mr. Chaouki is a finance executive with over two decades of experience across capital markets and financial services.

NEOGEN Corporation (NASDAQ: NEOG) announced today that they have partnered with Hendrix Genetics, a multi-species animal breeding, genetics, and technology company.

SaniSure, a global developer and manufacturer of single-use technology for the biopharmaceutical industry, announces the completion of a comprehensive extractables and biocompatibility study for many key products commonly used in biopharma manufacturing and development.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)” in the September 2021 issue of the journal EuroIntervention.